Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection

Procter et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.260
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showing 2.2% hospitalization and 0.3% death, which authors note is considerably lower than reported in other studies in their region.
At least two of zinc, HCQ, and ivermectin were used, along with one antibiotic, and budesonide and/or dexamethasone.
Study covers ivermectin and HCQ.
Procter et al., 30 Dec 2020, peer-reviewed, 6 authors.
This PaperIvermectinAll
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
Brian C Procter, Casey Ross, Vanessa Pickard, Erica Smith, Cortney Hanson, Peter A Mccullough
Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.260
There is an emergency need for early ambulatory treatment of Coronavirus Disease 2019 in acutely ill patients in an attempt to reduce disease progression and the risks of hospitalization and death. Such management should be applied in high-risk patients age > 50 years or with one or more medical problems including cardiovascular disease. We evaluated a total of 922 outpatients from March to September 2020. All patients underwent contemporary real-time polymerase chain reaction (PCR) assay tests from anterior nasal swab samples. Patients age 50.5 ± 13.7 years (range 12 to 89), 61.6% women, at moderate or high risk for COVID-19 received empiric management via telemedicine. At least two agents with antiviral activity against SARS-CoV-2 (zinc, hydroxychloroquine, ivermectin) and one antibiotic (azithromycin, doxycycline, ceftriaxone) were used along with inhaled budesonide and/or intramuscular dexamethasone consistent with the emergent science on early COVID-19 treatment. For patients with high severity of symptoms, urgent in-clinic administration of albuterol nebulizer, inhaled budesonide, and intravenous volume expansion with supplemental parenteral thiamine 500 mg, magnesium sulfate 4 grams, folic acid 1 gram, vitamin B12 1 mg. A total of 320/922 (34.7%) were treated resulting in 6/320 (1.9%) and 1/320 (0.3%) patients that were hospitalized and died, respectively. We conclude that early ambulatory (not hospitalized, treated at home), multidrug therapy is safe, feasible, and associated with low rates of hospitalization and death. Early treatment should be considered for high-risk patients as an emergency measure while we await randomized trials and guidelines for ambulatory management.
Authors' contributions BCP, CR, VP, ES, CH, contributed patient data, PAM drafted the first version, and all authors contributed edits to the final version. Ethics approval and consent to participate All patients provided informed consent for treatment according to good clinical practice. Conflict of interest Nothing to disclose. Authors had access to the data and wrote the manuscript.
References
Cervino, Oteri, COVID-19 pandemic and telephone triage before attending medical office: problem or opportunity?, Medicina (Kaunas)
Derwand, Scholz, Zelenko, COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study, International Journal of Antimicrobial Agents
Fiorillo, Cervino, Matarese, D'amico, Surace et al., COVID-19 surface persistence: a recent data summary and its importance for medical and dental settings, International Journal of Environmental Research and Public Health
Flannery, Adkins, Cook, Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU, Critical Care Medicine
Gambardella, Pagliuca, Pomilla, Gambardella, COVID-19 risk contagion: organization and procedures in a South Italy geriatric oncology ward, Journal of Geriatric Oncology
Lo, Bhargav, Salacup, Pelayo, Albano et al., Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis, Expert Review of Cardiovascular Therapy
Lo, Mccullough, Rangaswami, Antihypertensive drugs and risk of COVID-19?, The Lancet Respiratory Medicine
Mccullough, Eidt, Rangaswami, Lerma, Tumlin et al., Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection, Reviews in Cardiovascular Medicine
Mccullough, Kelly, Ruocco, Lerma, Tumlin et al., Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection, The American Journal of Medicine
Palazzuoli, Mancone, De Ferrari, Forleo, Secco et al., Antecedent administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists and survival after hospitalization for COVID-19 syndrome, Journal of the American Heart Association
Palazzuoli, Ruberto, De Ferrari, Forleo, Secco et al., Inpatient mortality according to level of respiratory support received for severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) infection: a prospective multicenter study, Critical Care Explorations
Tolone, Gambardella, Brusciano, Del Genio, Lucido et al., Telephonic triage before surgical ward admission and telemedicine during COVID-19 outbreak in Italy. Effective and easy procedures to reduce in-hospital positivity, International Journal of Surgery
Vahidy, Drews, Masud, Schwartz, Askary et al., Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area, Journal of the American Medical Association
Woloshin, Patel, Kesselheim, False negative tests for SARS-CoV-2 infection -challenges and implications, New England Journal of Medicine
Worldometer, COVID-19 Coronavirus Pandemic
Zhang, Mccullough, Tecson, Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19, Reviews in Cardiovascular Medicine
{ 'indexed': {'date-parts': [[2024, 5, 2]], 'date-time': '2024-05-02T00:06:27Z', 'timestamp': 1714608387288}, 'reference-count': 0, 'publisher': 'IMR Press', 'issue': '4', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020]]}, 'DOI': '10.31083/j.rcm.2020.04.260', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 12, 30]], 'date-time': '2020-12-30T09:45:31Z', 'timestamp': 1609321531000}, 'page': '611', 'source': 'Crossref', 'is-referenced-by-count': 32, 'title': 'Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) ' 'infection', 'prefix': '10.31083', 'volume': '21', 'member': '16242', 'container-title': 'Reviews in Cardiovascular Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://rcm.imrpress.com/fileup/2153-8174/PDF/1609227832928-1230317314.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T19:48:42Z', 'timestamp': 1643658522000}, 'score': 1, 'resource': {'primary': {'URL': 'https://imrpress.com/journal/RCM/21/4/10.31083/j.rcm.2020.04.260'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020]]}, 'references-count': 0, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2020]]}}, 'URL': 'http://dx.doi.org/10.31083/j.rcm.2020.04.260', 'relation': {}, 'ISSN': ['2153-8174'], 'subject': [], 'container-title-short': 'Reviews in Cardiovascular Medicine', 'published': {'date-parts': [[2020]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit